Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts SYRE Hot Sheet
Join SI Premium – FREE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.60), $0.24 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BrightSpring Health Services, Inc. (BTSG) Tops Q3 EPS by 34c ; Offers Guidance
- Forum Energy Technologies (FET) Tops Q3 EPS by 29c ; Offers Guidance
- Koss Corp (KOSS) Reports Q1 Loss of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
